IP Library Granted Patent US 11,337,957
Granted Patent B2
US 11,337,957 · App. 16/901,182 · Granted May 24, 2022

Compositions comprising urolithin compounds

Inventors: Penelope Andreux (Eclepens, CH); Christopher Rinsch (Lausanne, CH); William Blanco-Bose (La Croix, CH)
Assignee: Amazentis SA
A61K31/366A61K9/08A61K9/50A61K47/14A61K47/24A61P21/00C07D311/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,337,957
App. No.
16/901,182
Granted
May 24, 2022
Kind
B2
Abstract

The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.

Claims (21)

1. A method of enhancing muscle performance comprising administering to a subject an effective amount of a composition comprising:

a) medium-chain triglyceride; wherein the medium-chain triglyceride constitutes 30-80% w/w of the composition;

b) micronized urolithin A, having a D 50 size in a range of 0.5 to 50 μm, and a D 90 size in a range of 5 to 100 μm; and

c) lecithin, wherein the lecithin constitutes 1-40% w/w of the composition;

wherein the composition is formulated for oral administration.

2. The method of claim 1 , wherein the subject suffers from age-related decline in muscle function, age-related sarcopenia, age-related muscle wasting, physical fatigue, muscle fatigue, or is frail or pre-frail.

3. The method of claim 2 , wherein the subject is frail or pre-frail.

4. The method of claim 2 , wherein the subject suffers from age-related decline in muscle function, age-related sarcopenia, age-related muscle wasting, physical fatigue, or muscle fatigue.

5. The method of claim 4 , wherein the subject suffers from age-related decline in muscle function.

6. The method of claim 4 , wherein the subject suffers from age-related sarcopenia.

7. The method of claim 4 , wherein the subject suffers from age-related muscle wasting.

8. The method of claim 4 , wherein the subject suffers from physical fatigue.

9. The method of claim 4 , wherein the subject suffers from muscle fatigue.

10. The composition of claim 1 , wherein the weight ratio between the medium-chain triglyceride component and the urolithin A is in the range of 0.5:1 to 3:1.

11. The composition of claim 1 , wherein the medium-chain triglyceride comprises caprylic acid and/or capric acid.

12. The composition of claim 11 , wherein the medium-chain triglyceride is derived from a source selected from coconut oil, palm oil, and dairy fat.

13. The composition of claim 1 , further comprising an emulsifier.

14. The composition of claim 13 , wherein the emulsifier is a source of phosphatidylcholine.

15. The composition of claim 14 , wherein the source of phosphatidylcholine is lecithin.

16. The composition of claim 1 , further comprising a stabiliser.

17. The composition of claim 16 , wherein the stabiliser is glycerol monostearate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2020
From: ANDREUX, PENELOPE; RINSCH, CHRISTOPHER; BLANCO-BOSE, WILLIAM
To: AMAZENTIS SA
Reel/Frame 052974/0131 →
Priority Claims (1)
GB 1515387 · Aug 28, 2015 · national
Continuity (2)
Continuation 15757293
Related Publication 20200323818A1 · Oct 15, 2020
Cited By (3)
US 12,544,358 US 12,576,064 US 12,576,065